These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 10420495)

  • 1. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
    Zitterl W; Meszaros K; Hornik K; Twaroch T; Dossenbach M; Zitterl-Eglseer K; Zapotoczky HG
    Wien Klin Wochenschr; 1999 Jun; 111(11):439-42. PubMed ID: 10420495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
    Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
    J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
    J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
    Liebowitz MR; Turner SM; Piacentini J; Beidel DC; Clarvit SR; Davies SO; Graae F; Jaffer M; Lin SH; Sallee FR; Schmidt AB; Simpson HB
    J Am Acad Child Adolesc Psychiatry; 2002 Dec; 41(12):1431-8. PubMed ID: 12447029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
    Riddle MA; Scahill L; King RA; Hardin MT; Anderson GM; Ort SI; Smith JC; Leckman JF; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1062-9. PubMed ID: 1429406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder.
    Storch EA; Larson MJ; Shapira NA; Ward HE; Murphy TK; Geffken GR; Valerio H; Goodman WK
    Depress Anxiety; 2006; 23(7):429-33. PubMed ID: 16841343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Side effects as predictors of drug response in obsessive-compulsive disorder.
    Ackerman DL; Greenland S; Bystritsky A
    J Clin Psychopharmacol; 1999 Oct; 19(5):459-65. PubMed ID: 10505588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
    Mundo E; Bareggi SR; Pirola R; Bellodi L; Smeraldi E
    J Clin Psychopharmacol; 1997 Feb; 17(1):4-10. PubMed ID: 9004050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
    Onder E; Tural U; Gökbakan M
    Eur Arch Psychiatry Clin Neurosci; 2008 Sep; 258(6):319-23. PubMed ID: 18297416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
    Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
    J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
    Geller DA; Hoog SL; Heiligenstein JH; Ricardi RK; Tamura R; Kluszynski S; Jacobson JG;
    J Am Acad Child Adolesc Psychiatry; 2001 Jul; 40(7):773-9. PubMed ID: 11437015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.
    Berlin HA; Koran LM; Jenike MA; Shapira NA; Chaplin W; Pallanti S; Hollander E
    J Clin Psychiatry; 2011 May; 72(5):716-21. PubMed ID: 20816027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Hollander E; Baldini Rossi N; Sood E; Pallanti S
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):397-401. PubMed ID: 14604454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
    Blázquez A; Mas S; Plana MT; Gassó P; Méndez I; Torra M; Arnaiz JA; Lafuente A; Lázaro L
    J Clin Psychopharmacol; 2014 Jun; 34(3):318-26. PubMed ID: 24743718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
    Alaghband-Rad J; Hakimshooshtary M
    Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.